CONSTITUENT REPORT
Farnesol
Farnesol is a floral sesquiterpene alcohol that shows up both as a fragrance material in its own right and as a notable constituent in rose, ylang-ylang, pomelo flower, and other perfumery-linked oils. The live evidence base is split between strong identity and safety coverage, a well-known contact-allergen discussion, and a distinctive microbiology literature where farnesol acts as a quorum-sensing molecule affecting Candida biofilms and interspecies signaling. AromaForge should present farnesol as a fragrance-relevant sesquiterpene alcohol with real mechanistic and safety significance, while making clear that most activity evidence is microbial or preclinical rather than human therapeutic.
Chemical identity and composition
PubChem and NIST identify farnesol as C15H26O with InChIKey CRDAMVZIKSXKFV-YFVJMOTDSA-N. NIST indexes the 4602-84-0 entry as the trans-farnesol structure and lists several stereoisomeric alternatives, while the 2023 RIFM safety assessment notes that the commercial material may contain unspecified isomeric composition. In archive oil records, farnesol appears as a notable floral-sesquiterpenol marker in rose, ylang-ylang II, and pomelo-flower profiles.
Aroma and practical use
- Use the recorded floral, sweet, green, lily-of-the-valley-like, soft descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The 2023 RIFM safety assessment concluded that farnesol was not genotoxic, reported a repeated-dose NOAEL of 333 mg/kg/day, and assigned a skin-sensitization NESIL of 2700 microg/cm2 for fragrance-risk assessment.
RIFM also reported that farnesol was not expected to be photoirritating or photoallergenic and noted that exposure was below the TTC for local respiratory effects.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A 2002 Applied and Environmental Microbiology paper reported that preincubation with 300 microM farnesol completely inhibited Candida albicans biofilm formation in the tested model and reduced expression of the hypha-associated wall-protein gene HWP1.
This is one of the foundational farnesol papers and supports its archive relevance as more than a passive fragrance alcohol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2019 Virulence paper found that farnesol exposure caused loss of staphyloxanthin pigmentation in Staphylococcus aureus and activated oxidative-stress response pathways in a mixed-species interaction context.
The paper is mechanistically interesting because it moves beyond simple single-species growth inhibition and into fungal-bacterial signaling biology.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2004 Contact Dermatitis multicenter patch-test report found positive reactions to farnesol in 22 of 2021 consecutively tested patients, supporting its practical relevance as a contact allergen in dermatology settings.
This does not quantify general-population risk directly, but it is stronger than theoretical allergen labeling alone.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard, Farnesol (Amendment 49, 2020) - Category 5A (leave-on skin) maximum acceptable concentration in finished product, 0.29%; in-scope CAS: 4602-84-0, 106-28-5, 3790-71-4, 16106-95-9, 3879-60-5; basis: dermal sensitization; minimum purity requirement of 96% farnesol isomersFarnesol has a real contact-allergy literature and is not merely a theoretical fragrance sensitizer label.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
RIFM's 2023 assessment concluded that farnesol was not photoirritating or photoallergenic under the reviewed framework, but sensitization remains the main practical safety concern.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Because some public sources discuss farnesol as an allergen while others emphasize low or infrequent clinical positivity, the archive should keep both the sensitization signal and the uncertainty visible.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
EugenolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Eugenol report →GeraniolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Geraniol report →alpha-PineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read alpha-Pinene report →alpha-TerpineolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read alpha-Terpineol report →CarvacrolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Carvacrol report →Linalyl acetateAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Linalyl acetate report →NerolidolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Nerolidol report →How the effects were investigated
Candida quorum-sensing control of filamentation and biofilm formation
Farnesol is described in primary literature as a naturally occurring quorum-sensing molecule in Candida albicans that can suppress filamentation and, under tested conditions, inhibit biofilm development.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
competitive interference with staphyloxanthin biosynthesis plus redox-stress signaling in Staphylococcus aureus
A 2019 mixed-species study proposed that farnesol can competitively affect the CrtM pathway and trigger thiol-based oxidative-stress responses in S. aureus during fungal-bacterial interaction.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Most direct farnesol activity literature is microbial, signaling-focused, or otherwise preclinical rather than human efficacy evidence.
- The public safety picture is somewhat mixed because patch-test and review literature emphasize allergen relevance while predictive human-testing summaries can look weaker or inconsistent.
- This record does not split farnesol into all geometric isomers, even though NIST and archive oils show that isomer handling can matter analytically.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.